Chemistry:Ocinaplon
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C17H11N5O |
| Molar mass | 301.309 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ocinaplon is an anxiolytic drug in the pyrazolopyrimidine family of drugs. Other pyrazolopyrimidine drugs include zaleplon and indiplon.
Ocinaplon has a similar pharmacological profile to the benzodiazepine family of drugs, but with mainly anxiolytic properties and relatively little sedative or amnestic effect.[1]
Medical uses
A 2019 review found tentative evidence of benefit in anxiety.[2]
Mechanism of action
The mechanism of action by which ocinaplon produces its anxiolytic effects is by modulating GABAA receptors,[3] although ocinaplon is more subtype-selective than most benzodiazepines.[4]
Availability
Development of ocinaplon is discontinued due to liver complications that occurred in one of the Phase III subjects.[5]
Synthesis
Condensation of 4-Acetylpyridine[8] with N,N-Dimethylformamide dimethyl acetal (DMFDMA) gives the "enamide" (3). This is then condensed with (3-Amino-1H-pyrazol-4-yl)(2-pyridinyl)methanone (4) (96219-90-8).[9][10] This is the same intermediate as was used in the synthesis of zaleplon in which the nitrile is replaced by a 2-acetylpyridil moiety. This affords the anxiolytic agent ocinaplon (5).
References
- ↑ "Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator". Proceedings of the National Academy of Sciences of the United States of America 102 (20): 7380–5. May 2005. doi:10.1073/pnas.0502579102. PMID 15870187. Bibcode: 2005PNAS..102.7380L.
- ↑ "Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis". Lancet 393 (10173): 768–777. February 2019. doi:10.1016/S0140-6736(18)31793-8. PMID 30712879.
- ↑ "Comparative cue generalization profiles of L-838, 417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone, and various benzodiazepines in chlordiazepoxide and zolpidem drug discrimination". The Journal of Pharmacology and Experimental Therapeutics 316 (3): 1291–9. March 2006. doi:10.1124/jpet.105.094003. PMID 16339395.
- ↑ "The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics". Expert Opinion on Investigational Drugs 14 (5): 601–18. May 2005. doi:10.1517/13543784.14.5.601. PMID 15926867.
- ↑ "DOV Pharmaceutical, Inc. Places Ocinaplon Phase III Clinical Trial On Hold". PR NewsWire. http://www.prnewswire.com/news-releases/dov-pharmaceutical-inc-places-ocinaplon-phase-iii-clinical-trial-on-hold-55011422.html.
- ↑ "An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles". Beilstein Journal of Organic Chemistry 9: 2265–319. October 2013. doi:10.3762/bjoc.9.265. PMID 24204439.
- ↑ ARKIVOC 2010 (ii) 267-282
- ↑ "A-Amino Acetals: 2,2-Diethoxy-2-(4-Pyridyl)Ethylamine". Organic Syntheses 64: 19. 1986. doi:10.15227/orgsyn.064.0019.
- ↑ U.S. Patent 4,900,836
- ↑ CA patent 1243029
 |  |
